Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Modern Pathology

• Publication date

  2010-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/modpathol.2010.153PMID 20693985
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Osteopontin stimulates invasion of NCI‐h295 cells but is not associated with survival in adrenocortical carcinoma

  2009cited by this paper
• An Analysis of Potential Surrogate Markers of Target-Specific Therapy in Archival Materials of Adrenocortical Carcinoma

  2009cited by this paper
• New targets and therapeutic approaches for endocrine malignancies.

  2009cited by this paper
• Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma.

  2009cited by this paper
• Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.

  2009cited by this paper
• Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma

  2009cited by this paper
• The Role of Immunohistochemistry in Histopathological Diagnostics of Clinically “Silent” Incidentally Detected Adrenal Masses

  2008cited by this paper
• Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.

  2008cited by this paper
• Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.

  2007cited by this paper
• Adrenocortical cancer: pathophysiology and clinical management.

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours

  2006cited by this paper
• Adrenocortical Carcinoma: Clinical Update

  2006cited by this paper
• Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease.

  2006cited by this paper
• Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma

  2006cited by this paper
• Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.

  2006cited by this paper
• Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas

  2006cited by this paper
• Assessing EGFR mutations.

  2006cited by this paper
• Management of patients with adrenal cancer: recommendations of an international consensus conference.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what’s genetics got to do with it?

  2005cited by this paper
• Molecular genetics of adrenocortical tumours, from familial to sporadic diseases.

  2005cited by this paper
• Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer.

  2004cited by this paper
• The clinically inapparent adrenal mass: update in diagnosis and management.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Adrenocortical cancer: recent clinical and molecular advances

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Management of the Clinically Inapparent Adrenal Mass (Incidentaloma)

  2003cited by this paper
• Signaling Pathways in Adrenocortical Cancer

  2002cited by this paper
• Discerning malignancy in adrenocortical tumors: are molecular markers useful?

  2001cited by this paper
• EGF mutant receptor vIII as a molecular target in cancer therapy.

  2001cited by this paper
• The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

  2001cited by this paper
• Adrenocortical carcinoma: clinical and laboratory observations.

  2000cited by this paper
• Histopathological classification of adrenal tumours

  2000cited by this paper
• Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas.

  1997cited by this paper
• The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions

  1997cited by this paper
• MHC class II expression--a new tool to assess dignity in adrenocortical tumours.

  1996cited by this paper
• The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.

  1996cited by this paper
• Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization.

  1994cited by this paper
• Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma.

  1990cited by this paper
• Pathologic Features of Prognostic Significance in Adrenocortical Carcinoma

  1989cited by this paper
• The neu oncogene encodes an epidermal growth factor receptor-related protein

  1986cited by this paper
• Synthesis, turnover, and down-regulation of epidermal growth factor receptors in human A431 epidermoid carcinoma cells and skin fibroblasts.

  1982cited by this paper

• Frontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing Novel Therapeutic Approaches

  2025cites this paper
• Multi-modal characterization of metabolic and immune gene clusters in adrenocortical carcinoma treatment

  2025cites this paper
• Preliminary study of the role of nanobacteria in the formation of renal stones in experimental rats and its mechanism

  2024cites this paper
• Advances in translational research of the rare cancer type adrenocortical carcinoma

  2023cites this paper
• Expression of EMP 1, 2, and 3 in Adrenal Cortical Neoplasm and Pheochromocytoma

  2023influential citation
• Establishment of a male Wistar rat model of nanobacteriainduced kidney stones

  2021cites this paper
• Emerging drugs for the treatment of adrenocortical carcinoma

  2021cites this paper
• Targeted genomic analysis of 364 adrenocortical carcinomas.

  2021cites this paper
• Next-generation therapies for adrenocortical carcinoma.

  2020cites this paper
• Comparative study of a nano-bacterial rat kidney stone model and the traditional ethylene glycol rat kidney stone model

  2020cites this paper
• Medical management of adrenocortical carcinoma: current recommendations, new therapeutic options and future perspectives.

  2020cites this paper
• Is there a role for the IGF system and epidermal growth factor (EGF) in the pathogenesis of adrenocortical adenomas? A preliminary case-control study.

  2020cites this paper
• Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures

  2019cites this paper
• Management of Adrenocortical Carcinoma

  2019cites this paper
• New targeted therapies for adrenocortical carcinomas.

  2018cites this paper
• Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI

  2018cites this paper
• Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma

  2018cites this paper
• The role of epithelial growth factors and insulin growth factors in the adrenal neoplasms.

  2018cites this paper
• Development of new preclinical models to advance adrenocortical carcinoma research.

  2018cites this paper
• Adrenal Cortical Carcinoma and Pheochromocytoma

  2018cites this paper
• New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma (Review).

  2017cites this paper
• Update on adrenocortical carcinoma management and future directions

  2017cites this paper
• Novel targeted therapies in adrenocortical carcinoma

  2016cites this paper
• Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation

  2016cites this paper
• Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma

  2016cites this paper
• Genetic Alterations and Molecular Signatures in Aldosterone Producing Adenomas

  2016cites this paper
• The challenge of developmental therapeutics for adrenocortical carcinoma

  2016cites this paper
• Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.

  2016cites this paper
• Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors

  2015cites this paper
• Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition

  2015cites this paper
• Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy

  2015cites this paper
• Molecular pathways of human adrenocortical carcinoma - translating cell signalling knowledge into diagnostic and treatment options.

  2015cites this paper
• Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE)

  2015cites this paper
• Molecular markers and targeted therapies for adrenocortical carcinoma

  2014cites this paper
• Molecular target agents in adrenocortical carcinoma: rationale and difficulties in trial design

  2014cites this paper
• Genetics of Adrenal Tumors

  2014cites this paper
• Roles of the Pathologist in Evaluating Surrogate Markers for Medical Therapy in Adrenocortical Carcinoma

  2014cites this paper
• Emerging therapy for adrenocortical carcinoma.

  2014cites this paper
• Adrenal cortical neoplasms: a study of clinicopathological features related to epidermal growth factor receptor gene status

  2014cites this paper
• Genetics and epigenetics of adrenocortical tumors.

  2014cites this paper
• A current perspective on treatment of adrenocortical carcinoma

  2014cites this paper
• Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.

  2013cites this paper
• Current management options for recurrent adrenocortical carcinoma

  2013cites this paper
• Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.

  2013cites this paper
• Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment

  2012cites this paper
• New Perspectives on Diagnostics, Prognosis, and Therapy in Aggressive Endocrine Tumours

  2012cites this paper
• Survivin in Adrenocortical Tumors – Pathophysiological Implications and Therapeutic Potential

  2012cites this paper
• Is There a Role of Targeted Agents in the Management of Adrenocortical Cancers?

  2012cites this paper
• Acquisition Order of Ras and p53 Gene Alterations Defines Distinct Adrenocortical Tumor Phenotypes

  2012cites this paper
• The next generation of therapies for adrenocortical cancers.

  2012cites this paper
• Genetic aspects of adrenocortical tumours and hyperplasias

  2012cites this paper
• Adrenocortical carcinoma: a clinician's update

  2011cites this paper
• Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome

  2011cites this paper
• : a consensus statement of the Italian Society of Endocrinology

  year unknowncites this paper